neuropsychiatric disorders

Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia

by

Boehringer Ingel­heim, Click Ther­a­peu­tics ink $500M+ dig­i­tal ther­a­peu­tics devel­op­ment, com­mer­cial­iza­tion deal (Mobi­Health­News):

Inter­na­tion­al phar­ma Boehringer Ingel­heim and pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics have inked a $500 mil­lion-plus deal to joint­ly devel­op and com­mer­cial­ize a dig­i­tal treat­ment for patients with schiz­o­phre­nia. [Read more…] about Click Ther­a­peu­tics and Boehringer Ingel­heim part­ner to devel­op and mar­ket a dig­i­tal ther­a­peu­tic to treat schizophrenia

Neuroengineering meets neuroethics to address treatment-resistant depression

by

Dr. Maryam Shanechi. Cred­it: USC Viterbi

___________________

Is This the Future of Men­tal Health? (USC Viter­bi School of Engineering):

“Brain–machine inter­faces (BMIs) pro­vide a direct path­way to the brain to trans­late brain sig­nals into actions … Below, Shanechi (Note: Maryam Shanechi, PhD, assis­tant pro­fes­sor of elec­tri­cal and com­put­er engi­neer­ing) answers some ques­tions about her work and what the future might hold for our under­stand­ing and treat­ment of men­tal disorders.

What poten­tial does this hold for the future not just of men­tal health, but of under­stand­ing our brains as a whole?

Neu­ropsy­chi­atric dis­or­ders are a major cause of dis­abil­i­ty world­wide with depres­sive dis­or­ders being the most dis­abling among them. About 30% of major depres­sion patients are treat­ment-resis­tant – that’s about 5 mil­lion peo­ple in the US alone. [Read more…] about Neu­ro­engi­neer­ing meets neu­roethics to address treat­ment-resis­tant depression

Study: Psychedelics can promote neural plasticity in the prefrontal cortex and expand pathways for mental health

by

– Cred­it: Cell Reports 2018 23, 3170–3182DOI: (10.1016/j.celrep.2018.05.022). Copy­right © 2018 The Authors

Psy­che­delics in Neu­rol­o­gy: Poten­tial for Improv­ing Neu­ro­plas­tic­i­ty (Neu­rol­o­gy­Times):

“Back in the 1950s, research was prov­ing that psy­che­del­ic agents could be effec­tive in the treat­ment of var­i­ous neu­ropsy­chi­atric dis­or­ders. Unfor­tu­nate­ly, just as sci­ence was explor­ing their ben­e­fi­cial effects, the coun­ter­cul­ture was explor­ing and embrac­ing their effects. Slow­ly but sure­ly, psy­che­delics were asso­ci­at­ed with rebel­lious youth and the tumul­tuous anti-war move­ment. As a result, the gov­ern­ment shut down most of the research.

The 1990s saw renewed inter­est in psy­che­del­ic com­pounds as a means to address neu­ropsy­chi­atric dis­or­ders. Research explored the ben­e­fits of MDMA and ket­a­mine to treat mood dis­or­ders and post­trau­mat­ic stress dis­or­der. Now, a new study sheds even more light on the promise these agents might pro­vide. [Read more…] about Study: Psy­che­delics can pro­mote neur­al plas­tic­i­ty in the pre­frontal cor­tex and expand path­ways for men­tal health

Mental health meets the digital revolution: Mindstrong Health raises $14 million to modernize the diagnosis and treatment of neuropsychiatric disorders via artificial intelligence (AI) and smartphones

by

—

Mind­strong Health Rais­es $14 Mil­lion in Series‑A Fund­ing (press release):

“Mind­strong Health, a start­up trans­form­ing the diag­no­sis and treat­ment of neu­ropsy­chi­atric dis­or­ders through the pow­er of AI and ubiq­ui­tous mobile tech­nol­o­gy, today announced that it has secured a $14 mil­lion round of Series‑A fund­ing. Led by Fore­site Cap­i­tal and ARCH Ven­ture Part­ners, the round includ­ed [Read more…] about Men­tal health meets the dig­i­tal rev­o­lu­tion: Mind­strong Health rais­es $14 mil­lion to mod­ern­ize the diag­no­sis and treat­ment of neu­ropsy­chi­atric dis­or­ders via arti­fi­cial intel­li­gence (AI) and smartphones